Want to see POCI full AI Analyst Report?
POCI Stock Chart & Stats
$4.21
-$0.09(-1.91%)
At close: 4:00 PM EST
$4.21
-$0.09(-1.91%)
Day’s Range― - ―
52-Week Range$3.55 - $6.15
Previous CloseN/A
Volume150.00
Average Volume (3M)22.99K
Market Cap
$54.51M
Enterprise Value$38.34M
Total Cash (Recent Filing)$10.68M
Total Debt (Recent Filing)$4.28M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Sep 24, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding10,944,869
10 Day Avg. Volume30,022
30 Day Avg. Volume22,992
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.71
Price to Sales (P/S)1.74
P/FCF Ratio-8.82
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit9.57
Enterprise Value/Ebitda-8.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Record Revenue GrowthA 108% YoY Q3 revenue surge to $8.7M and a raised FY2026 revenue guide ($29–31M) indicate durable demand and scaling ability. This momentum reflects expanding production revenue and a pipeline of programs moving to production, supporting sustainable top‑line growth over months.
Gross Margin And EBITDA InflectionMaterial margin improvement to ~24% alongside a positive adjusted EBITDA quarter signals improving unit economics and operational leverage. Yield gains (notably aerospace ~97% and cystoscope >90%) and Ross Optical growth suggest structural margin expansion potential if yield and mix trends persist.
Strengthened Liquidity From $10M OfferingAn oversubscribed $10M equity raise lifted cash to $10.7M, materially extending runway and funding production scale-up and facility work. Coupled with low reported debt, the financed liquidity reduces near‑term funding risk and supports execution of multiple programs into production.
Bears Say
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow is a structural constraint: TTM OCF ~-$1.5M and FCF ~-$1.9M with steep FCF decline increases reliance on external capital. If cash generation doesn’t sustainably turn positive, the company may need further dilution or debt to fund growth.
Ongoing Net Losses And Negative Full‑year EBITDAAlthough trending better, the company still guides to negative adjusted EBITDA for FY2026 and reported a net loss in Q3. Persistent full‑year unprofitability undermines returns on invested capital and requires sustained margin improvement to convert recent operational gains into durable profitability.
Customer Concentration And Pullback RiskA large aerospace customer accounted for a material share of revenue and has requested a 15%–20% production slowdown, exposing revenue volatility. Combined with disclosure limits on customer IDs, concentration reduces forecasting visibility and raises the risk that a single customer action can materially affect results.
Precision Optics Corporation News
POCI FAQ
What was Precision Optics Corporation’s price range in the past 12 months?
Precision Optics Corporation lowest stock price was $3.55 and its highest was $6.15 in the past 12 months.
What is Precision Optics Corporation’s market cap?
Precision Optics Corporation’s market cap is $54.51M.
When is Precision Optics Corporation’s upcoming earnings report date?
Precision Optics Corporation’s upcoming earnings report date is Sep 24, 2026 which is in 72 days.
How were Precision Optics Corporation’s earnings last quarter?
Precision Optics Corporation released its earnings results on May 13, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.
Is Precision Optics Corporation overvalued?
According to Wall Street analysts Precision Optics Corporation’s price is currently Overvalued.
Does Precision Optics Corporation pay dividends?
Precision Optics Corporation does not currently pay dividends.
What is Precision Optics Corporation’s EPS estimate?
Precision Optics Corporation’s EPS estimate is -0.06.
How many shares outstanding does Precision Optics Corporation have?
Precision Optics Corporation has 10,944,869 shares outstanding.
What happened to Precision Optics Corporation’s price movement after its last earnings report?
Precision Optics Corporation reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.913%.
Which hedge fund is a major shareholder of Precision Optics Corporation?
Currently, no hedge funds are holding shares in POCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precision Optics Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.78%
12-Months-Change
Fundamentals
Return on Equity
-37.47%
Trailing 12-Months
Asset Growth
71.67%
Trailing 12-Months
Company Description
Precision Optics Corporation
Precision Optics Corporation, Inc. (POCI) specializes in the engineering, manufacturing, and sale of advanced optical and illumination systems, along with their complementary components. Its main operational regions are the United States and the European Economic Area. The company's offerings include medical instruments such as various types of endoscopes and endocouplers. Moreover, POCI provides bespoke imaging and lighting solutions, encompassing high-precision Microprecision lenses, miniature medical cameras, and cutting-edge 3D endoscopes, all designed for application in minimally invasive surgical procedures carried out by hospitals and healthcare professionals. Beyond its medical division, POCI also produces individual parts and integrated assemblies for industrial and military purposes. POCI markets its medical device portfolio primarily to other corporations within the medical technology sector. Established in 1982, the firm's headquarters are located in Gardner, Massachusetts.
POCI Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational momentum and important financial inflection points: record revenue, materially improved gross margins, and positive adjusted EBITDA in Q3, supported by manufacturing yield gains, Ross Optical growth and a reinforced cash position from a $10M offering. Management increased full-year revenue guidance and outlined a robust pipeline with multiple programs expected to enter production. Key near-term risks include a customer-requested aerospace production slowdown (estimated 15%–20% pullback in early FY2027), remaining yield improvements needed on the cystoscope line, and facility modernization requirements. On balance, the positive operational and financial progress significantly outweighs the contained challenges, indicating constructive near-term trajectory toward sustained profitability.View all POCI earnings summariesTechnical Analysis
Ownership Overview
5.27% Insiders
17.49% Mutual Funds
29.39% Other Institutional Investors
44.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---